Afatinib for Patients with Acquired Resistance to EGFR TKIs? Perhaps in Combination with Erbitux, but Is It Tolerable?

Article

With the recent approval of afatinib, now becoming commercially available as Gilotrif, there is the potential new strategy for patients with an EGFR mutation who develop acquired resistance to a different EGFR tyrosine kinase inhibitor (TKI) in an earlier line of therapy.

Subscribe to afatinib/cetuximab